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Background. Bicuspid aortic valve (BAV) is a common congenital heart defect with increased prevalence of aortic dilatation and
dissection. BAV has an autosomal dominant pattern of inheritance with reduced penetrance and variable expressivity. BAV has
been described as an isolated trait or associated with other clinical manifestations in syndromic conditions. Identification of a
syndromic condition in a BAV patient is clinically relevant in order to personalize indication to aortic surgery. We aimed to
point out how genetic diagnosis by next-generation sequencing (NGS) can improve management of a patient with complex BAV
clinical picture. Methods and Results. We describe a 45-year-old Caucasian male with BAV, thoracic aortic root and ascending
aorta dilatation, and connective features evocative but inconclusive for clinical diagnosis of Marfan syndrome (MFS). Targeted
(91 genes) NGS was used. Proband genetic variants were investigated in first-degree relatives. Proband carried 5 rare variants in
4 genes: FBN1(p.Asn542Ser and p.Lys2460Arg), NOTCH1(p.Val1739Met), LTBP1(p.Arg1330Gln), and TGFBR3(p.Arg423Trp). The
two FBN1 variants were inherited in cis by the mother, showing systemic features evocative of MFS, but with a milder phenotype
than that observed in the proband. Careful clinical observation along with the presence of the FBN1 variants allowed diagnosis of
MFS in the proband and in his mother. NOTCH1 variant was found in mother and brother, not exhibiting BAV, thus not definitely
supporting/excluding association with BAV. Interestingly, the proband, his brother and father, all showing root dilatation, and
his sister, with upper range aortic root dimension, were carriers of a TGFBR3 variant. LTBP1 might also modulate the vascular
phenotype. Conclusions. Our results underline the usefulness of NGS together with family evaluation in diagnosis of patients with
monogenic traits and overlapping clinical manifestations due to contribution of the same genes and/or presence of comorbidities
determined by different genes.
1. Background
Bicuspid aortic valve (BAV) disease is the most common
congenital heart defect, as it affects 1.3% of the adult general
population [1]. Aortic dilatation is a common feature of BAV
with a prevalence ranging from 20 to 84% [1], due to differ-
ences in assessment techniques, study population, aortic size
thresholds, and heterogeneous nature of the disease related to
different genetic and nongenetic individual and population
background. An increased risk of aortic dissection has been
reported for BAV patients, thus raising concerns for the
proper timing of aortic surgery in these patients [2–4].
Familial clustering has been reported, mostly with an
autosomal pattern of inheritance with reduced penetrance
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and variable expressivity [5]. Actually, the heritability of BAV
has been estimated to be 89%, thus suggesting the presence of
a relevant genetic contribution [6].
Furthermore, BAV has been described as an isolated trait
or associated with other clinical manifestations in syndromic
conditions [familial thoracic aortic aneurysm and dissection,
Marfan syndrome (MFS), Loeys-Dietz syndrome, Andersen
syndrome, Turner syndrome, William Beuren syndrome,
Bosley-Salih-Alorainy syndrome, and Athabascan Brainstem
Dysgenesis syndrome] [5, 7, 8]. Identification of a syndromic
condition in a BAV patient is clinically relevant in order to
personalize indication to aortic surgery [9, 10].
Different genes with divergent inheritance pattern have
been described to be associated with BAV [6]. NOTCH1
(9q34.3, OMIM 190198), a transmembrane receptor involved
in signaling pathways regulating cell fate and cardiovascular
development processes, represents the main gene demon-
strated to be associated with BAV in both familial and spo-
radic forms [7, 11, 12]. Mutations in NOTCH1 signaling genes
have been associated with a wide spectrum of congenital
heart defects [13].
Shortly thereafter, GATA5 (20q13.33, OMIM 611496) has
been also demonstrated to be involved in cardiac morpho-
genesis and aortic valve development [14] implicated in BAV
pathogenesis [7, 15, 16]. The contribution of additional genes,
such asAXIN1, EGFR, ENG,NKX2-5,NOS3, PDIA2, TGFBR1,
andTGFBR2, has been also suggested in BAV disease [5, 7, 13,
17].
Previous data from our group evidenced the presence
of genetic variants in FBN1 gene, encoding for fibrillin1, a
component of connective tissue, in 2 isolated BAV patients
with aortic root dilatation and in 2 MFS patients with
BAV [18, 19]. Actually, a higher prevalence of BAV among
MFS patients with respect to the general population was
demonstrated, thus possibly suggesting common underly-
ing mechanisms responsible for the phenotypic expression
of these clinical disorders. Fibrillin-1 deficiency could be
responsible for matrix alterations, which contribute to aor-
topathy associated with BAV and MFS [20]. Similar connec-
tive tissue histopathological features in BAV and MFS have
been reported by some authors; moreover, the aortic wall in
both MFS and BAV patients is characterized by an increased
metalloproteinase (MMP) activity and a decreased fibrillin-1
expression [20, 21].
Nevertheless, differences in the anatomic site of aortic
wall vulnerability in both conditions, MFS and BAV, were
evidenced: the maximal aortic dilatation is observed at
the level of the proximal thoracic ascending aorta in BAV
patients, while it is mainly referred to the aortic root in
MFS patients [22]. Therefore, due to differences and sim-
ilarities between BAV and MFS aortic wall pathology, the
pathogenetic mechanisms underlying these conditions are
still matter of debate.
We describe here a comprehensive target gene cap-
ture/NGS approach, analyzing 91 genes associated with BAV,
syndromic and nonsyndromic aortopathy, vessels or valves
growth, and remodeling processes, on a patient affected
by normally functioning BAV, aortic root, and thoracic
ascending aorta dilatation, with connective features evocative
but inconclusive for a connective tissue disorder like MFS.
We found rare nonsynonymous exonic variants, in large
part predicted to be damaging by in silico analysis, that
segregated with his “complex phenotype”, characterized by
several clinical manifestations, ranging from vascular alter-
ations (BAV and aortic root/ascending aorta dilatation) to
systemic features suggestive of overlapping syndromic traits.
2. Methods
We describe a subject referred to the Center for Marfan Syn-
drome and Related Disorders (Careggi Hospital, Florence,
Italy), affected by BAV, aortic root, and thoracic ascending
aorta dilatation with a strong familiarity for thoracic aorta
dilatation. His pedigree is reported in Figure 1. Our proband
(II-1) was investigated by targeted NGS approach, and find-
ings were validated through traditional Sanger sequencing.
Thereafter, rare genetic variants identified in the proband
have been investigated in first-degree family members [I-
1 (mother), I-2 (father), II-2 (brother), and II-3 (sister)].
The experimental protocol was approved by the local ethical
committee. All patients underwent genetic counseling and
signed a written informed consent.
2.1. Echocardiographic Evaluation. All echocardiographic
measurements had beenmade by a senior cardiologist (S.N.).
BAV was diagnosed when only two cups were unequivocally
identified in systole and diastole in the short axis view with
a clear “fishmouth” appearance during systole as previously
described [23, 24]. Aortic dimensions were assessed at end-
diastole in the parasternal long-axis view at four levels by the
leading edge method [23–25] and Z-scores were calculated
according to age-adjusted nomograms for the aortic root
[26]. Aortic or mitral regurgitation was evaluated and graded
bymultiple criteria combining color Doppler and continuous
wave Doppler signals, and aortic valve stenosis was evaluated
and graded by peak aortic valve velocity [23].
2.2. Genetic Analysis. Peripheral venous blood was collected
in EDTA-coated vacutainer tubes and was stored at -20∘C.
Genomic DNA was extracted from blood samples using
Tecan Freedom EVO liquid handling platform (Tecan
Group Ltd, Switzerland) and GeneCatcher gDNA 0.3–1 mL
Blood Kit (Thermo Fisher Scientific, USA). All procedures
were performed following manufacturer protocols.
NGS was performed by 454 GS FLX Titanium tech-
nology (Roche, Basel, Switzerland). Using a targeted cap-
ture approach, we designed a panel of 91 genes regarded
as relevant in BAV and syndromic and nonsyndromic
aortopathy or involved in vessels or valves growth and
remodeling processes by reviewing literature (COL11A1,
MTHFR, PLOD1, ADAMTSL4, MFAP2, PTGS2, SKI, TGFB2,
CAPN2, AGT, MTR, TGFBR3, FGF8, RET, ACTA2, B3GAT3,
LTBP3, EFEMP2/fbln4, LRP5, CCND1, LRP6, COL2A1, LRP1,
DCN, LTBP2, TGFB3, FBLN5, ADAMTS17, CHST14, FBN1,
SMAD3, MYH11, ABCC6, MAPK3, PDIA2, AXIN1, MMP2,
CRYBA1, COL1A1, ACE, KCNJ2, EMILIN2, SMAD2, SMAD4,
LTBP4, TGFB1, ADAMTS10, MMADHC, ACVR1, COL3A1,
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COL5A2, FN1, COL6A3, EMILIN1, LTBP1, JAG1, EMILIN3,
MMP9, SLC2A10, GATA5, CBS, COL6A1, COL6A2, UFD1L,
MAPK1, VHL, ZPLD1, MYLK, AGTR1, PDCD10, TGFBR2,
FBN2, NKX2-5, B4GALT7, ADAMTS2, AGGF1, MTRR,
NOS3, HOXA1, CCM2, KRIT1, COL1A2, TGFBR1, PTGS1,
ENG, COL5A1, NOTCH1, GNAQ, AGTR2, FLNA, ELN:
870,000 bp). Genomic DNA libraries were prepared accord-
ing to Roche sample preparation protocol (Rapid Library
Preparation Method Manual, Roche Nimblegen Inc., Madi-
son, WI). The customized capture array was designed to
capture all coding exons, and flanking intron sequences of
the 91 genes, according to the manufacturer’s protocol (Nim-
bleGen Arrays User’s Guide: 454 Optimized Sequence Cap-
ture).Hybridization andwashing procedureswere performed
according to Roche standard protocol. Sequencing run was
then performed with the 454 Roche instrument. Sequencing
runs have a mean coverage depth 45x.The standard flow files
were analyzed with the GS Mapper software, version 2.6
(RocheDiagnostic, Basel, Switzerland).The gene variants calls
were also evaluated by using an in-house pipeline developed
by our bioinformaticians. Raw reads data were aligned to
the human reference genome (hg19) with BWA version 0.7.12
[27]. Alignment and coverage statistics were generated with
GATK version 3.3 [28], SAMTOOLS version 1.2 [29], and
custom R scripts. Detection of single nucleotide variants and
insertions/deletions was performed with the GATK Unified
Genotyper by interrogating exons and intronic flanking
regions (100bp) and taking into account strand-bias filtering
and locus with more than 10X of sequencing coverage.
Detected variants were annotated with Variant Effect Predic-
tor version [30].
Sanger sequencing procedures were carried out in order
to validate the identified genetic variants.The specific primer
sets were designed using the Primer3 algorithm (http://
frodo.wi.mit.edu/primer3). A bidirectional direct sequenc-
ing of PCR products was performed through ABI 3500Dx
Sequencer (Applied Biosystems Foster City, CA, USA).
Prediction of the effect of mutations was performed by
Polyphen-2 (http://genetics.bwh.harvard.edu/pph2/), Sort-
ing Tolerant from Intolerant (SIFT, http://sift.jcvi.org),
FATHMM (http://fathmm.biocompute.org.uk/), and Muta-
tionTaster (http://www.mutationtaster.org/) in silico tools.
3. Results
The proband (II-1) is a 45-year-old Caucasian normotensive
male (height 181 cm, weight 70 Kg). He presented with
mild pectus excavatum and chest asymmetry, retrognathia,
dolichocephaly, inguinal hernia, skin striae not associated
with marked weight changes, and Beighton score 4/9.
Echocardiography of the aorta documented the presence of
a BAV with fusion of the right and left coronary cusps and
a raphe and no calcification, dilatation of the aortic root
(41mm; Z-score 2.56), and of ascending aorta (47 mm), and
nonclassic mildmitral valve prolapse (i.e., without significant
thickness of the valve leaflets) [31]. Magnetic resonance
imaging (MRI) of the lumbosacral region did not show the
presence of dural ectasia. No ocular clinical manifestations
were observed in II-1. No family history of MFS or other
connective tissue disorders and of aortic dissection or aor-
tic/mitral valve replacement or aortic aneurysmwas reported
by the proband.
The clinical evaluation of the first-degree familymembers
of II-1 was performed.
The mother (I-1) is a 75-year-old Caucasian nor-
motensive female (height 164 cm, weight 54 Kg). She
presents a positive (≥7) systemic feature score including
myopia >3DO, mild pectus asymmetry and pectus cari-
natum deformity, mild thoracolumbar kyphosis, reduced
elbow extension, and hindfoot deformity. Echocardiogra-
phy of the aorta documented normal size of the aor-
tic root diameters at the sinuses of valsalva within nor-
mal range (31 mm; Z-score -0.74), ascending aorta dilata-
tion (35 mm), and mild mitral and tricuspid valve pro-
lapse.
The father (I-2) is a 76-year-old Caucasian hypertensive
male (height 177 cm, weight 89 Kg). He displays a systemic
features’ score of 4 for the presence of pectus carinatum
deformity, pectus excavatum, and thoracolumbar kyphosis
[8]. Echocardiography of the I-2 aorta documented the
presence of aortic root at the sinuses of valsalva dilatation (41
mm; Z-score 1.19) with a normal size of the ascending aorta
(32 mm).
The brother (II-2) of the proband is a 49-year-old nor-
motensive Caucasian male (height 183 cm, weight 105 Kg)
with pectus excavatum, pes planus, and striae distensae. He
presented dilated aortic root (42 mm; Z-score 2.13) and
normal size of the ascending aorta (30 mm).
The sister (II-3) of the proband is a 43-year-old nor-
motensive Caucasian female (height 170 cm, weight 57 Kg)
with severe scoliosis and osteoporosis. She presented normal
aortic root (31 mm; Z-score 0.23) and ascending aorta (25
mm).
BAV was present only in the proband out of the 5 family
members evaluated. In history taking of each member of the
family there was no evidence of either occurrence of BAV or
aortic surgery or sudden death.
NGS targeted approach identified in the proband (II-
1) 5 rare heterozygous variants [minor allele frequency
(MAF)<0.01] (Table 1) in 4 different genes: FBN1
(p.Asn542Ser and p.Lys2460Arg), NOTCH1 (p.Val1739Met),
LTBP1 (p.Arg1330Gln), and TGFBR3 (p.Arg423Trp)
(Figure 1). These variants were confirmed through Sanger
technology (Figure 2).
Characteristics of identified variants and results from
in silico prediction of the pathogenetic effect were reported
in Table 1. Variants detected in the proband were also
investigated in his first-degree relatives (Figure 1). NOTCH1
and LTBP1mutations were present in proband’s mother (I-1)
and brother (II-2). Concerning FBN1 gene, both p.Asn542Ser
and p.Lys2460Arg variantswere inherited in cis by themother
(I-1) and not found in any of other family members. Finally,
the TGFBR3 variant was transmitted by the father to the
offspring (Figure 1).
In the proband, we also identified 139 common genetic
variants (39 nonsynonymous) in the coding regions (data
available if required).
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FBN1 p.Asn542Ser +/-
+/-
+/-
p.Lys2460Arg
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NOTCH1 p.Val1739Met
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-/-
-/-
p.Lys2460Arg
LTBP1 p.Arg1330Gln
TGFBR3 p.Arg423Trp +/-
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-/-
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TGFBR3 p.Arg423Trp +/-
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FBN1 p.Asn542Ser -/-
-/-
+/-
p.Lys2460Arg
LTBP1 p.Arg1330Gln
TGFBR3 p.Arg423Trp +/-
NOTCH1 p.Val1739Met
FBN1 p.Asn542Ser +/-
+/-
+/-
p.Lys2460Arg
LTBP1 p.Arg1330Gln
TGFBR3 p.Arg423Trp +/-
=TAV
MAS AA (35mm)
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MAS AR (41mm)
MAS AR (41mm)
MAS AA (47mm)
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MAS AR (42mm) MAS AR (31.4mm)
1941 1939
1971 1967 1973
-/-
-/-
+/-
+/- +/-
Figure 1: Pedigree of bicuspid aortic valve (BAV) family. BAV subjects are evidenced in green, whereas those showing tricuspid aortic valve
(TAV) are not highlighted. An arrow indicates the proband case. Variants at NOTCH1, FBN1, LTBP1, and TGFBR3 loci identified in BAV
family members are shown. Birth years are reported at the upper left corner of symbols identifying subjects. MAS: maximal aortic size; AA:
ascending aorta; AR: aortic root; nsCTD: nonspecific connective tissue disorders.
4. Conclusions
In the present study, the designed targeted NGS allowed
us to identify 5 rare, nonsynonymous exonic variants in
a patient affected by complex phenotype with BAV, aortic
root and thoracic ascending aorta dilatation, and connective
features evocative for MFS. Traditional Sanger sequencing
confirmed that these variants in NOTCH1, FBN1, LTBP1, and
TGFBR3 genes were inherited, in various combinations, from
the parents, one of which (mother) with a phenotype, upon
closer observation, attributable toMFS. In fact, she presented
the two different variants in FBN1 gene and transmitted
them in cis to the proband. According to the last revised
Ghent criteria for MFS diagnosis, the identification of FBN1
pathogenetic mutation in the proband, exhibiting aortic root
dilatation (Z-score >2), allowed diagnosing MFS [8], and the
identification of FBN1 mutations in proband’s mother also
permitted diagnosing her as potential Marfan patient, even
if with a less severe phenotype.
The two mutations in the FBN1 are c.1625 A>G
(p.Asn542Ser) in the exon 13 and c.7379A>G (p.Lys2460Arg)
in the exon 59. Both variants determine amino acid changes
in calcium-binding epidermal growth factor-like domains
(cbEGF4 and cbEGF38, respectively), known to mediate
fibrillin assembly into microfibrils and in turn the biome-
chanical properties of the microfibrillar network [32]. Actu-
ally, both nucleotide substitutions do not affect highly con-
served amino acids of the cbEGFs; nevertheless, some of
in silico pathogenicity prediction tools showed a deleterious
effect. Although c.7379A>G variant has been hypothesized
to affect splicing process by generating a cryptic splice site,
in vitro studies did not evidence its influence on mRNA
processing [33]. This variant, reported in dbSNP database
(rs144189837) with MAF≤0.0002 in Europeans, has been
previously identified in patients with features of MFS [33, 34]
and in thoracic aortic aneurysm (TAA) with a Marfan-like
phenotype [35]. No information was available in literature
or mutation databases for the c.1625 A>G variant. These
two mutations were already identified together (not specified
whether in trans or in cis due to lack of parents analysis) in our
lab in further two patients: the first showing thoracic aortic
dissection (TAD) type A and aortic valve substitution, mild
myopia, striae distensae, altered lower/upper body segment
ratio, and radicular cysts; the other, displaying a further
FBN1 mutation (c.6850C>A; exon 55), affected by severe
classic MFS diagnosed on the presence of ectopia lentis,
TAA and systemic features with score 10 including myopia,
>3DO, pectus carinatum, scoliosis, wrist, and thumb signs,
pes planus/hindfoot deformity.
According to international guidelines [10], the definition
of MFS diagnosis in the proband determines the indication
for an earlier aortic surgery. Moreover, in this patient, due to
the presence of aortic root and ascending aorta dilatation, and
genetic variants in FBN1 and other potentiallymodifier genes,
this issue seems of particular relevance. In fact, in this patient,
further potentially pathogenetic variants for aortopathy were
identified.
NOTCH1mutation is a nucleotide substitution from gua-
nine to adenine at position 5215 in the coding gene sequence
(c.5215G>A, exon 28), responsible for valine to methionine
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Forward
Reverse
Forward
Reverse
NOTCH1 (NM_017617)
c.[5215G>A]+[=]
p.[Val1739Met] +[=]
FBN1 (NM_000138.4)
c.[1625A>G]+[=]
p.[Asn542Ser] +[=]
FBN1 (NM_000138.4)
c.[7379A>G]+[=]
p.[Lys2460Arg] +[=]
LTBP1 (NM_206943)
c.[3989G>A]+[=]
p.[Arg1330Gln] +[=]
TGFBR3 (NM_003243)
c.[1267C>T]+[=]
p.[Arg423Trp] +[=]
Figure 2: Electropherograms showing NOTCH1, FBN1, LTBP1, and TGFBR3 gene mutations.
amino acid substitution at codon 1739 (p.Val1739Met), in
the transmembrane domain of the encoded protein [11].
As cleavage of the intracellular domain, acting as a tran-
scription factor able to modulate target genes expression
[36], occurs at the transmembrane domain [37], it could be
conceivable that modifications of this domain may result
in an altered signal transduction. This variant, classified as
damaging by most of in silico prediction tools (Table 1),
has been described in dbSNP database (rs377294245), with
a MAF of 0.00009 and has not been previously described
in literature in BAV patients. Nonetheless, other NOTCH1
mutations have been associated with BAV manifestations
(http://www.hgmd.cf.ac.uk/ac/all.php). We have therefore
identified this variant in proband’s mother and brother,
who, however, do not exhibit BAV. Nevertheless, due to the
incomplete penetrance of BAV trait, the role of NOTCH1 as
BAV causative gene cannot be longer excluded.
The c.3989G>A variant at LTBP1 gene, also identified in
the mother and in the brother, is predicted to be deleterious
by Polyphen and Mutation Taster algorithm, and it might
contribute to further modulate the phenotypic expression
of the disease. LTBP1, a member of the LTBPs family,
is known to have dual function: as structural component
of the extracellular matrix and as modulator of TGF-beta
availability essential for tissue formation and homeostasis
[38, 39].
A mutation in the exon 8 of TGFBR3 gene, encoding for
the TGF-beta type III receptor often occurring as a coreceptor
with other TGF-beta receptor superfamily members [40],
was also found (c.1267C>T), with lying in the extracellular
region of the protein and that cause amino acid substitution
from arginine to tryptophan at codon 423 (p.Arg423Trp).
Previous data from literature indicated the contribution of
TGFBR1 and TGFBR2 genes in thoracic aortic aneurysms
and dissections [41, 42]. Only one study showed a TGFBR2
mutation in a patient with BAV and TAA [43]. No mutations
in TGFBR1 and TGFBR2 were identified in 11 unrelated
Italian patients with familial BAV [13], as well as in previous
further two studies on BAV patients [44, 45]. Interestingly,
both father and brother, exhibiting aortic root dilatation, and
sister of proband, in whom upper range of normal aortic
root dimensions were observed, showed TGFBR3 mutation,
thus suggesting a cosegregation of TGFBR3 variant with the
presence of aortic root dilatation.
Beyond these rare genetic variants, other polymorphisms
identified in the proband such as MTHFR p.Ala222Val
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(heterozygous) associated with severe cardiovascular man-
ifestations in MFS patients or abdominal aortic aneurysm
[46–48] or NOS3 p.Glu298Asp (heterozygous) associated
with hypertension [49] and abdominal aortic aneurysm
[50] could interact to modulate the clinical phenotype.
Furthermore, a missense polymorphic variant (p.Ala84Thr),
with a global MAF of 0.0274 (MAF 0.0109 in the European
population), has been identified in PLOD1 gene, whose
expression/activity alterations have been suggested to be
involved in impaired collagen cross-linking in BAV patients
[51], so possibly contributing to modulating the clinical
phenotype in addition to the NOTCH1mutation.
The presence of BAV in only one member of the family
did not allow the definition of the contribution of rare or
common genetic variants on aortic valve defect. In order to
achieve a definite comprehension of larger BAVgenetic bases,
more informative families with several affected subjects are
needed.
After a posttest genetic counseling, a clinical and echocar-
diographic follow-up to all the family members was recom-
mended on a yearly basis for the proband, mother, father,
and brother, biennial for the sister. Moreover, in absence of
clinical news, an evaluation in theMarfan Center in Florence
was also scheduled at every two years for all the family
members. In particular, it was elucidated to the proband that,
due to theMFS diagnosis, the threshold for aortic surgerywas
anticipated from that recommended for uncomplicated BAV
(i.e., 55 mm) to the cut-off value recommended for MFS, i.e.,
50 mm [9, 10].
On the bases of the current acknowledge [9, 10, 52, 53], a
similar genetic approach should be taken into consideration,
in BAV patients with thoracic aortic dilatation and further
clinical manifestations suggestive of syndromic traits, and
should be considered with more caution in other forms of
BAV-associated aortic dilation patients.
In conclusion, our results underlined the complexity of
clinical and genetic diagnosis also in traits considered mono-
genic, but in which clinical manifestations can overlap due to
both contribution of the same genes to different phenotypes
as well as presence of comorbidities determined by different
genes. Moreover, this paper highlighted the usefulness of
high-throughput sequencing technologies to improve diag-
nosis in a scenario in which an increasing number of genetic
traits need to be considered polygenic/multifactorial. Target
gene capture/deep sequencing approach can greatly improve
the genetic diagnosis/management of patients with BAV.
This study once more demonstrated the power of NGS in
confirming and expanding clinical phenotypes/genotypes of
the extremely heterogeneous conditions, assisting in genetic
counseling and in carrier detection as well as providing
therapeutic options.
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